<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892330</url>
  </required_header>
  <id_info>
    <org_study_id>SJZE001</org_study_id>
    <nct_id>NCT03892330</nct_id>
  </id_info>
  <brief_title>Combination Therapy of Anthracyclines for Children With Nephroblastoma</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the efficacy and side effects of study drugs in children with
      nephroblastoma who are treated with combination therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2045</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Five-year Event free survival (5-year EFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>0.5-14 Year Old Children With Nephroblastoma</condition>
  <arm_group>
    <arm_group_label>liposomal doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pharmorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pirarubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.</description>
    <arm_group_label>doxorubicin</arm_group_label>
    <arm_group_label>liposomal doxorubicin</arm_group_label>
    <arm_group_label>pharmorubicin</arm_group_label>
    <arm_group_label>pirarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytetracycline/ Cyclophosphamide</intervention_name>
    <description>Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.</description>
    <arm_group_label>doxorubicin</arm_group_label>
    <arm_group_label>liposomal doxorubicin</arm_group_label>
    <arm_group_label>pharmorubicin</arm_group_label>
    <arm_group_label>pirarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal doxorubicin</intervention_name>
    <description>The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.</description>
    <arm_group_label>liposomal doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.</description>
    <arm_group_label>doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmorubicin</intervention_name>
    <description>The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.</description>
    <arm_group_label>pharmorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirarubicin</intervention_name>
    <description>The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.</description>
    <arm_group_label>pirarubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 6 months old to 14 years old.

          2. No smoking history.

          3. Pathologically confirmed nephroblastoma.

          4. Informed consent and assent has been obtained before any study assessment is
             performed.

          5. Good compliance.

          6. Need to be applied to anthracycline chemotherapy according to the diagnosis and
             treatment recommendations for Chinese children with nephroblastoma (current version
             CCCG-WT-2016).

          7. Need to be applied to doxorubicin according to the diagnosis and treatment
             recommendations for children with nephroblastoma (CCCG-WT-2016).

        Exclusion Criteria:

          1. Patients with cardiovascular disease in addition to nephroblastoma.

          2. Patients with digestive, neurological, circulatory, renal or liver disease, blood
             disorders or growth abnormalities unrelated to the tumor.

          3. Patients have been treated with chemotherapy or cardiotoxic nephrotoxic drugs in the
             past 4 weeks.

          4. Patients have participated in other clinical trials in the past 4 weeks.

          5. Patients with mediastinal disease.

          6. Patients who have undergone mediastinal radiotherapy due to other tumors or received
             other treatments that may cause heart damage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weisong Cai</last_name>
    <phone>18940257606</phone>
    <email>cailab9@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weisong Cai, MD</last_name>
      <phone>86-18940257606</phone>
      <email>cailab9@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Weisong Cai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Weisong Cai</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nephroblastoma</keyword>
  <keyword>Anthracycline</keyword>
  <keyword>Liposome doxorubicin</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Pharmorubicin</keyword>
  <keyword>Pirarubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wilms Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytetracycline</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Dear Sir/Madam Our study receives a grant from China Ministry of Science and Technology. We cannot decide whether the data could be shared. Hope you can understand.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

